Adamantyl-substituted retinoid-related molecules induce apoptosis in human acute myelogenous leukemia cells

Molecular Cancer Therapeutics

Volumn 9, Issue 11, 2010, Pages 2903-2913

  Farhana, Lulu ^a   Dawson, Marcia I ^d   Xia, Zebin ^d   Aboukameel, Amro ^b   Xu, Liping ^a   Liu, Gang ^d   Das, Jayanta K ^a   Hatfield, James ^c   Levi, Edi ^c   Mohammad, Ramzi ^b   Fontana, Joseph A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 5 PYRIMIDINYL] 2 PROPENOIC ACID; 4 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 3 CHLOROCINNAMIC ACID; ALITRETINOIN; ANTINEOPLASTIC AGENT; CELL PROTEIN; CELLULAR INHIBITOR OF APOPTOSIS 1; DNA NUCLEOTIDYLEXOTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; RETINOIC ACID; UNCLASSIFIED DRUG; X INKED INHIBITOR OF APOPTOSIS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ACRYLATES; ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CINNAMATES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED ICR; MICE, INBRED NOD; MICE, SCID; RETINOIDS; TUMOR CELLS, CULTURED; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649661903     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0546     Document Type: Article

References (40)

1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia; results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
2. Grimwade D, Walker H, Harrison G, et al. The predictive value of hieratical cytogenetic classification in older adults with acute myeloid leukemia (AML) analysis of 1065 patients entered into United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1312-20.
3. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-36.
4. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Eng J Med 1991;324:1385-93.
5. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
6. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia-new agents. Semin Hematol 2006;43:96-106.
7. Meshinchi S, Appelbaum FR. Structural and alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009;15:4263-9.
8. Schadendorf D, Kern MA, Artuc M, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996;135:1889-98.
9. Mologni L, Ponzanelli I, Brescianni F, et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999;93:1045-61.
10. Garattini E, Parrella E, Diomede L, et al. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood 2004;103:194-207.
11. Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997;89:4470-9.
12. Sun SY, Yue P, Chandraratna RA, Tesfaigzi Y, Hong WK, Lotan R. Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous carcinoma cells. Mol Pharmacol 2000;58:508-14.
13. Parella E, Gianni M, Fratelli M, et al. Antitumor activity of the retinoid molecules (E)-3-(4′-hydroxy-3′-adamantylbiphenyl)acrylic acid (ST1926) and 6-[3-(adamantly)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor γ and retinoid-independent pathways. Mol Pharmacol 2006;70:909-24.
14. Zhang Y, Dawson MI, Ning Y, et al. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood 2003;192:3743-52.
15. Farhana L, Dawson MI, Leid M, et al. Adamantyl-substituted molecules bind SHP and modulate the Sin3A repressor. Cancer Res 2007;67:318-25.
16. 388IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 2003;17:155-9.
17. Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-êB activation. Cancer Res 2006;65:4909-17.
18. Farhana L, Dawson MI, Dannenberg JH, Xu L, Fontana JA. SHP and Sin3A expression are essential for adamantyl-substituted retinoid related molecules-mediated NF-κB activation, c-Fos/c-Jun expression and cellular apoptosis. Mol Cancer Ther 2009;8:1625-35.
19. Zhang Y, Dawson MI, Mohammad R, et al. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 2002;100:2917-25.
20. Jin H-S, Lee D-H, Kim D-H, et al. cIAP1, cIAP2, and XIAP act cooperatively via nonreduntant pathways to regulate genotoxic stress-induced nuclear factor-κB activation. Cancer Res 2009;69:1782-91.
21. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathway-dependent tumor specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003;63:8330-7.
22. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 1999;284:309-13.
23. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell 1996;85:149-58.
24. Shin HM, Kim MH, Kim BH, et al. Inhibitor action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without effecting IκB degradation. FEBS Lett 2004;571:50-4.
25. Seol W, Choi HS, Moore DD. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 1996;272:1336-9.
26. Choi YH, Park MJ, Kim KW, Lee HC, Choi YH, Cheong J. The orphan nuclear receptor SHP is involved in monocytic differentiation and its expression is increased by c-Jun. J Leukoc Biol 2004;76:1082-8.
27. 2-terminal kinase/p38 mitogen activated protein kinases. Cancer Res 2001;61:8504-12.
28. Holmes WF, Soprano DR, Soprano KJ. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437 activatio of the p38 MAPP kinase signal pathway. Oncogene 2003;22:6377-86.
29. Jin F, Liu X, Zhou Z, et al. Activation of nuclear factor-κB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 2005;65:6354-63.
30. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as the therapeutic targets in cancer. Cell Death Differ 2006;13:238-47.
31. Pfahl M, Pieddrafita FJ. Retinoid targets for apoptosis induction. Oncogene 2003;22:9058-62.
32. Kim Y-S, Han C-Y, Kim S-W, et al. The orphan nuclear receptor small heterodimer partner as a coregulator of nuclear factor-κB in oxidized low density lipoprotein-treated macrophage cell line RAW 264.7. J Biol Chem 2001;276:33736-40.
33. Nishizawa H, Yamagata K, Shimomura I, et al. Small heterodimer partner, an orphan nuclear receptor, augments perioxisome proliferators-activated receptor γ transactivation. J Biol Chem 2002;277:1586-92.
34. He N, Park K, Zhang Y, Huang J, Lu S, Wang L. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 2008;134:793-802.
35. Zhang Y, Xu P, Park K, Choi Y, Moore DD, Wang L. Orphan receptor small Heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 2008;48:289-98.
36. Bruserud Ø, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haemtologica 2007;92:332-41.
37. Cowley SM, Kang RS, Frangioni JV, et al. Functional analysis of the Mad1-3A repressor-corepressor interaction reveals determinants of specificity, affinity and transcriptional response. Mol Cell Biol 2004;24:2698-709.
38. Shiio Y, Rose DW, Aur R, Donohoe S, Aebersold R, Eisenman RN. Identification and characterization of SAP25, a novel component of the Sin3 repressor complex. Mol Cell Biol 2006;26:1386-97.
39. Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P, Reinberg D. Histone deacetylases and SAP18, a novel polypeptide are components of a human Sin3 complex. Cell 1997;89:357-64.
40. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by tertiary complex formation with homologs of yeast repressor Sin3. Cell 1995;80:777-86.